Scope, claim structure, and US patent landscape for “United States Drug Patent 6,099,859” (controlled-release antihyperglycemic tablet with semipermeable membrane)

US Patent 6,099,859 claims a specific controlled-release tablet architecture for antihyperglycemic drugs, anchored on (i) a core containing high loading of an antihyperglycemic and optional excipients, and (ii) a semipermeable membrane coating that blocks drug transport while allowing permeation of water/biological fluids, and (iii) one or more passageways through the membrane to meter release. Dependent claims narrow this architecture to biguanides, especially metformin (and salts) and also buformin, and add excipient and performance parameters that can materially constrain design-around options.

What patents protect controlled-release antihyperglycemic tablets like US 6,099,859?

US 6,099,859 is best viewed as a “platform-plus-narrow features” claim set: broad structural elements up front, then extensive dependent narrowing by excipient families and functional/empirical attributes.

Claim 1: What is the independent scope (the core of the estate)?

Claim 1 (independent) protects a controlled release pharmaceutical tablet with three coordinated elements:

Core composition (ranges)
- 50–98% antihyperglycemic drug
- 0–40% binding agent
- 0–20% absorption enhancer
Semipermeable membrane coating (permeation selectivity)
- Membrane is:
  - permeable to passage of water and biological fluids
  - impermeable to passage of the antihyperglycemic drug
- Membrane composition ranges:
  - 50–99% polymer
  - 0–40% flux enhancer
  - 0–25% plasticizer
Passageways in the membrane
- At least one passageway formed in the semipermeable membrane for release.

Functional “release mechanism” hook: the membrane is semipermeable by fluid transport but blocks drug, with release enabled through passageways. This is a high-value claim axis for infringement because many alternative controlled-release systems (matrix tablets, erodible matrices, osmotic pumps without explicit passageways, diffusion coatings without permeation selectivity) may fail one or more of these structural/functional requirements.

Dependent claims: where the protected perimeter tightens

The remaining provided claims narrow by drug identity, excipient selection, membrane polymer family, and dissolution/PK timing.

Drug-selectivity narrowing (Claims 2–4, 27–28)

Claim 2: antihyperglycemic is a biguanide
Claim 3: biguanide is metformin or pharmaceutically acceptable salt
Claim 4: biguanide is buformin or pharmaceutically acceptable salt

A separate “metformin-focused” claim appears as Claim 27 (and Claim 28 adds timing).

Binding agent and absorption enhancer narrowing (Claims 5–13)

Claim 5: binding agent is water soluble
Claim 6: water soluble binding agent selected from:
- polyvinyl pyrrolidone (PVP)
- hydroxypropyl cellulose (HPC)
- hydroxyethyl cellulose (HEC)
- waxes
- mixtures
Claim 7: binding agent specifically PVP
Claim 8: absorption enhancer selected from:
- fatty acids, surfactants, chelating agents, bile salts, mixtures
Claims 9–13: specific exemplars:
- fatty acids: capric acid, oleic acid, monoglycerides
- surfactants: sodium lauryl sulfate, sodium taurocholate, polysorbate 80
- chelators: citric acid, phytic acid, EDTA, EGTA
- bile salts: (broadly stated as bile salt)
- explicit sodium lauryl sulfate callout

Membrane polymer class narrowing (Claims 14–15)

Claim 14: water insoluble cellulose derivative for the membrane
Claim 15: cellulose acetate specifically

Membrane additive narrowing (Claims 16–20)

Claim 16: membrane comprises flux enhancer
Claim 17: flux enhancer list includes many polymeric/small-molecule excipients (e.g., salts, sugars, PEGs, HPC, HPMC phthalates, cellulose acetate phthalate, PVA, methacrylic copolymers)
Claim 18: flux enhancer specifically PEG 380–420 (by average molecular weight)
Claims 19–20: plasticizer in membrane; specifically triacetin

Passageway count (Claim 21)

at least two passageways (instead of at least one)

Performance/empirical constraints (Claims 22–26)

Claim 22: peak plasma level at 8–12 hours
Claim 23: optional immediate-release component (drug coated onto membrane or mixed into membrane)
Claim 24–25: dissolution profiles in USP Apparatus 2, 75 rpm, 900 mL simulated intestinal fluid (pH 7.5 phosphate buffer), 37°C, with two alternative sets of release-time windows
Claim 26: dosing with or shortly after evening meal

Independent “formulation-constrained” claims (Claims 27 and 29)

Claim 27: metformin-specific controlled release tablet where:
- core consists essentially of: metformin + water soluble binding agent + absorption enhancer
- membrane comprises: cellulose acetate + flux enhancer + plasticizer
- plus passageway(s)
Claim 29: “consisting essentially of” controlled release tablet with tighter formulation ranges:
- core:
  - 75–95% antihyperglycemic
  - 3–15% binding agent
  - 2–15% absorption enhancer
- membrane:
  - membrane polymer 75–95%
  - flux enhancer 2–20%
  - plasticizer 2–15%
- includes passageway(s)

Implication for enforcement strategy: claim coverage spans from broad drug class and architecture (Claim 1) to specific excipient combinations (PVP, cellulose acetate, triacetin, PEG 380–420, and sodium lauryl sulfate) and to in vitro dissolution windows and PK timing. That gives multiple claim “hooks” for asserting infringement: either by structural design (passageways + semipermeable cellulose acetate membrane with drug-impermeability) or by functional performance (dissolution/PK), depending on how a challenger product is built and tested.

How broad is claim 1’s “semipermeable membrane” coverage?

High-level scope under Claim 1:

Must be a semipermeable membrane coating with:
- fluid-permeable
- drug-impermeable
Must contain a polymer at 50–99%
May contain flux enhancer (0–40%) and plasticizer (0–25%)
Must have at least one passageway through the membrane.

Practical breadth drivers:

The membrane polymer is broadly defined only as “polymer” in Claim 1, with narrower cellulose acetate in dependent claims. If a product uses a non-cellulose-acetate polymer, it may still fall within Claim 1 if it retains the permeation selectivity and passageway release architecture.
The passageways requirement is the tight structural element. Many controlled-release coatings rely on polymer permeability and diffusion without discrete passageways. Products that instead use erosion, swelling-controlled diffusion, or osmotic pumping without passageway structures may reduce risk on that axis.

What design-around options are most relevant given these claims?

1) Avoid “drug-impermeable semipermeable membrane with passageways”

The strongest shared elements across Claim 1, Claim 27, and Claim 29 are:

drug-impermeability (membrane blocks drug)
semipermeable fluid passage
explicit passageways.

Design-around target: products that use an erodible matrix or multi-layer diffusion system where the drug migrates through a permeable polymer without discrete passageways are less likely to satisfy the “passageway in the semipermeable membrane” limitation.

2) Avoid specific excipient selections that feed dependent claims

Even if a product maps to Claim 1, dependent claims can be used to narrow infringement theories. The provided dependent claims cover:

binding agents: water soluble (PVP, HPC, HEC, waxes)
absorption enhancers: fatty acids, surfactants (including sodium lauryl sulfate), chelators (EDTA/EGTA types), bile salts
membrane polymer: cellulose acetate
flux enhancer: PEG 380–420 specifically in Claim 18
plasticizer: triacetin

Design-around target: substitute membrane systems with different plasticizer/flux enhancer profiles outside the enumerated dependent claim lists, or use different binding/absorption enhancer selections.

3) Avoid the dissolution and PK “sweet spots” used in dependent claims

Claim 24 and Claim 25 carve distinct dissolution ranges at 2, 4, 8, 12, 16, 20 hours in intestinal pH 7.5 conditions. Claim 22 and Claim 28 target PK peak time 8–12 hours.

Design-around target: if a product is vulnerable to performance-based dependent claim theories, altering membrane thickness, passageway density/size, or release-driving excipient content to shift release kinetics can move it outside those dependent ranges.

How many claim “tiers” exist across this estate based on the provided claim set?

From the text provided, there are at least three tiers of narrowing:

Architecture tier (Claim 1)
Controlled-release tablet + semipermeable coating + drug-impermeable + passageways + composition ranges.
Drug identity tier (Claims 2–4, 27–28, 29)
Biguanides, especially metformin and buformin, plus “core consists essentially of” constraints in Claim 27 and “consisting essentially of” in Claim 29.
Formulation/performance tier (Claims 5–21, 22–26)
Specific binding agents, absorption enhancers, cellulose acetate, triacetin, PEG 380–420, passageway count, dissolution windows, PK timing, and meal timing.

This multi-tier structure increases enforcement leverage because an accused product can be tested against multiple independent/dependent claim paths.

Which market products are most likely to implicate this estate?

The claim set is strongly metformin-centric. Claim 3 identifies metformin explicitly, and Claim 27 and Claim 28 are framed as metformin controlled release tablets with cellulose acetate membranes and timed peak levels.

Competitive implication: any controlled-release metformin tablet using (i) a semipermeable cellulose-acetate-type membrane, (ii) passageway structures, and (iii) drug-impermeability logic is structurally aligned with the strongest portions of this claim set.

What is the Orange Book status of US 6,099,859 and when does it lose exclusivity?

No Orange Book listing details (drug, NDA/ANDA number, listed patent expiry, or exclusivity type) are provided in the prompt, and the patent identifier alone is insufficient to reliably determine Orange Book linkage without additional database access.

When does US 6,099,859 expire?

No filing date, priority date, or adjusted expiration data are provided in the prompt, and these dates are required to compute or confirm the US patent expiration and any term adjustments.

What Paragraph IV and Hatch-Waxman risk exists for generic entry?

Paragraph IV risk assessment requires knowledge of:

which NDA/ANDA the patent is listed against,
whether it is asserted via litigation or settlement,
and whether the generic product design can avoid the passageway + drug-impermeable membrane limitations.

None of that case linkage or regulatory mapping is included in the prompt.

How strong is the patent estate for controlled-release metformin tablet formulations?

Based on claim language alone, the estate strength (within the provided claim set) is driven by:

Clear structural limitations (semipermeable coating with drug-impermeability + passageways) that can be tested through formulation characterization and manufacturing descriptions.
Multiple dependent claims that narrow to common excipient families in controlled-release tablets (cellulose acetate, triacetin, PEGs, PVP, HPMC/HPC, and common absorption enhancers like sodium lauryl sulfate).
Dependent performance claims (USP dissolution windows; PK peak timing) that provide additional infringement routes when structural evidence is contested.

Claim 1 is broad enough to cover multiple polymer families if the membrane meets the drug-impermeability and passageway limitations, while Claims 14–20 and 27 anchor enforceability to cellulose acetate membranes with specific common excipients.

Patent claim scope summary table (provided claims)

Claim	Key protected element	Scope impact
1	Controlled release tablet; core (50–98% antihyperglycemic), semipermeable membrane (50–99% polymer; drug-impermeable), passageway(s)	Broad architecture; key infringement gate is passageways + drug-impermeable membrane
2	Biguanide	Limits Claim 1 to biguanides
3	Metformin	Further narrows to metformin
4	Buformin	Further narrows to buformin
5	Binding agent water soluble	Adds excipient characterization limitation
6	Binding agent exemplars incl. PVP/HPC/HEC/waxes	Narrows dependent scope
7	Binding agent = PVP	Narrow excipient
8–13	Absorption enhancer families and exemplars incl. fatty acids, surfactants (SLS), chelators, bile salts	Narrows release-modulating excipients
14–15	Membrane cellulose derivative; cellulose acetate	Narrows to cellulose acetate
16–18	Flux enhancer included; PEG 380–420	Narrows membrane additive
19–20	Plasticizer included; triacetin	Narrows plasticizer
21	At least two passageways	Tightens structural feature
22, 28	Peak plasma 8–12 hours	PK timing dependent hook
23	Immediate-release variant (coated or mixed drug)	Extra formulation variant
24–25	USP apparatus 2 dissolution windows at pH 7.5	Empirical dependent hook
26	Dosing with/after evening meal	Dosing regimen limitation
27	Metformin-specific; “core consisting essentially of”; cellulose acetate membrane	Strong narrow enforceability
29	“Consisting essentially of” with tighter % ranges for core and membrane	Narrows formulation space

Key takeaways

US 6,099,859 claim coverage is built around a semipermeable, drug-impermeable membrane coating on a high-loading antihyperglycemic core, with release enabled via passageways.
The independent claim (Claim 1) is broad at the architecture level but constrained by the combination of drug-impermeability + passageways and wide core/membrane composition ranges.
Dependent claims provide multiple narrowing vectors: metformin/biguanide identity, cellulose acetate membrane, triacetin plasticizer, PEG 380–420 flux enhancer, PVP binding agent, sodium lauryl sulfate-type absorption enhancement, and USP dissolution/PK timing.
Design-around risk is highest for products using passageway-based controlled release with drug-impermeable semipermeable cellulose acetate-type membranes and excipient systems overlapping the enumerated dependent claims.
Orange Book linkage, exclusivity timelines, and Paragraph IV litigation posture cannot be determined from the provided information.

FAQs

1) Does US 6,099,859 require passageways, or can controlled release occur without them?
The provided independent claim requires “at least one passageway in the semipermeable membrane for the release of the antihyperglycemic drug,” and Claim 21 tightens to at least two passageways.

2) Are metformin and buformin both protected under this claim set?
Yes. Claims 3 and 4 explicitly recite metformin and buformin (including pharmaceutically acceptable salts).

3) What excipients are most explicitly called out for dependent claim coverage of the membrane?
Cellulose acetate for the membrane (Claims 14–15), triacetin as a plasticizer (Claim 20), and PEG 380–420 as a flux enhancer (Claim 18), among other enumerated flux enhancer options.

4) What in vitro testing conditions are used for dissolution-dependent infringement theories?
USP Apparatus 2 at 75 rpm in 900 mL simulated intestinal fluid (pH 7.5 phosphate buffer) at 37°C (Claims 24–25).

5) What PK timing limitation appears in the dependent claims?
Peak plasma level obtained 8–12 hours after administration (Claim 22), and Claim 28 ties the same timing into the metformin-focused formulation.

References

United States Patent No. 6,099,859.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3101999	⤷ Start Trial
Australia	739226	⤷ Start Trial
Canada	2324493	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,099,859

Summary for Patent: 6,099,859